Olea-Sánchez EG, Sánchez-Moreno EC, Hernández-Salcedo DR, Valencia-López R, Luque-Hernández A

Language: Spanish
References: 16
Page: 722-726
PDF size: 277.39 Kb.

ABSTRACT

Background: Amyloidosis is a rare disorder, in which the native proteins with incorrect folding are deposited extracellularly. Primary amyloidosis (AL) is the most common type caused by light chains of abnormal immunoglobulins. The incidence is 5 to 12 people per million per year, the manifestations are related to the infiltration of several organs, mainly heart and kidney.
Clinical case: A 67 years-old patient who consulted for a year of evolution of facial and lower limbs edema. Based on the clinical and paraclinical findings he was diagnosed with AL associated with monoclonal gammapathy of lambda light chains, which was treated with bortezomib, with relieve of the general symptoms.
Conclusions: This case report had primary amyloidosis, which is a severe and little frequent disorder appearing at median age of 65 year and whose diagnosis is usually late due to its insidious manifestation.

REFERENCES

1. Dember L. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006; 17 (12): 3458-3471. doi: 10.1681/ ASN.2006050460

2. Quock T, Yan T, Chang E, Guthrie S, Broder M. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2018; 2 (10): 1046-1053. doi: 10.1182/ bloodadvances.2018016402

3. Kidd J, Carl D. Renal amyloidosis. Current Problems Cancer 2016; 40 (5-6): 209-219.

4. Zech P, et al. The nephrotic syndrome in adults aged over 60: etiology, evolution and treatment of 76 cases. Clinical Nephrol 1982; 17 (5): 232-236.

5. Fawcett I, Hilton P, Jones N, Wing A. Nephrotic syndrome in the elderly. Br Med J 1971; 2 (5758): 387-388. doi: 10.1136/ bmj.2.5758.387

6. Jazbeh S, Said A, Haddad R, Hamad A, Lerma E. Renal amyloidosis. Disease-a-Month 2014; 60 (10): 489-493.

7. Moutzouris, D, Herlitz L, Appel G, Markowitz G, Freudenthal B, Radhakrishnan J, D’Agati V. Renal biopsy in the very elderly. Clin J Am Soc Nephrol 2009; 4 (6): 1073-82. doi: 10.2215/CJN.00990209

8. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349 (6): 583-596. doi: 10.1056/ NEJMra023144

9. Wechalekar A, Gillmore J, Bird J, Cavenagh J, Hawkins S, Kazmi M et al. Guidelines on the management of AL amyloidosis. Br J Haematol 2014; 168 (2): 186-206. https:// doi.org/10.1111/bjh.13155

10. Lacruz Guzmán D, Funes Vera C, Martínez Penella M, Morales Lara M, Jorge Vidal V, Mira Sirvent M. Bortezomib como alternativa en el tratamiento de pacientes con gammapatías malignas. Farmacia Hospitalaria 2008; 32 (5): 280-285. DOI: 10.1016/S1130-6343(08)75947-6

11. Sanchorawala V. Light-chain (AL) amyloidosis: Diagnosis and treatment. Clin J Am Soc Nephrol 2006; 1 (6): 1331- 1341. DOI: https://doi.org/10.2215/CJN.02740806

12. Pozzi C, D'Amico M, Fogazzi G, Curioni S, Ferrario F, Pasquali S et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42 (6): 1154-1163. doi: 10.1053/j. ajkd.2003.08.040

13. Kourelis T, Kumar S, Gertz M, Lacy M, Buadi F, Hayman S et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013; 31 (34): 4319-4324. doi: 10.1200/ JCO.2013.50.8499

14. Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood 2017; 129 (15): 2132-2142. doi: 10.1182/ blood-2016-08-730978

15. Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Hematologic 2013; 98 (10): 1492-1495. doi: 10.3324/haematol.2013.094482

16. Ruiz-Argüelles G, Ruiz-Delgado G. On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS). Int J Hematol 2012; 96 (1): 144-145. DOI: 10.1007/s12185-012-1114-x